Position in SVRA
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$8,188,235
+$3,467,443 QoQ
Shares Held
1,329,259
+53.7% QoQ
Ownership
0.647%
of shares outstanding
% of Portfolio
0.10%
of 13F equity value
Holder Rank
#30
of 181 holders
Holding Since
Jun 2023
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SVRA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ALGERT GLOBAL LLC holds $633,232,925 across 110 Biotechnology names. SVRA ranks #29 (1.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PCVX |
Vaxcyte, Inc.
|
515,343 | $29,956,888 | |
| 2 | ROIV |
Roivant Sciences Ltd.
|
845,118 | $29,908,726 | |
| 3 | XENE |
Xenon Pharmaceuticals Inc.
|
419,773 | $25,337,498 | |
| 4 | CLDX |
Celldex Therapeutics, Inc.
|
647,836 | $24,105,977 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
95,335 | $23,335,147 | |
| 6 | SNDX |
Syndax Pharmaceuticals Inc
|
1,051,465 | $22,985,024 | |
| 7 | MRNA |
Moderna, Inc.
|
274,820 | $19,245,644 | |
| 8 | MLYS |
Mineralys Therapeutics, Inc.
|
649,027 | $17,510,748 |
All Filings in SVRA
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8,188,235 | 1,329,259 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $4,720,792 | 864,614 | Shares | Sole | 2026-05-14 | |
| 2025-06-30 | $182,281 | 79,948 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $368,321 | 132,968 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $408,211 | 132,968 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $525,624 | 123,968 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $962,392 | 238,807 | Shares | Sole | 2024-08-15 | |
| 2024-03-31 | $983,201 | 197,430 | Shares | Sole | 2024-05-15 | |
| 2023-09-30 | $138,499 | 36,640 | Shares | Sole | 2023-11-13 | |
| 2023-06-30 | $51,279 | 16,050 | Shares | Sole | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||